Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

KPTI Karyopharm Therapeutics

Watchlist
3.520
+0.150+4.45%
Close  02/07 16:00 ET
High
3.540
Open
3.340
Turnover
7.37M
Low
3.325
Pre Close
3.370
Volume
2.15M
Market Cap
398.51M
P/E(TTM)
Loss
52wk High
14.730
Shares
113.21M
P/E(Static)
Loss
52wk Low
2.450
Float Cap
352.45M
Bid/Ask %
50.00%
Historical High
49.005
Shs Float
100.13M
Volume Ratio
1.14
Historical Low
2.450
Dividend TTM
--
Div Yield TTM
--
P/B
-2.84
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
2.14%
Amplitude
6.38%
Avg Price
3.437
Lot Size
1
Float Cap
352.45M
Bid/Ask %
50.00%
Historical High
49.005
Shs Float
100.13M
Volume Ratio
1.14
Historical Low
2.450
Dividend TTM
--
P/B
-2.84
Dividend LFY
--
Turnover Ratio
2.14%
Amplitude
6.38%
Avg Price
3.437
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
CEO: Mr. Richard Paulson
Market: NASDAQ
Listing Date: 11/06/2013
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist